(Q37942516)

25 August 2017

0 references

1 reference

title

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials (English)

1 reference

25 August 2017

1 reference

1

Fausto Petrelli

1 reference

25 August 2017

5

Sandro Barni

1 reference

25 August 2017

3

Mary Cabiddu

1 reference

25 August 2017

2

Karen Borgonovo

1 reference

25 August 2017

4

Veronica Lonati

1 reference

25 August 2017

publication date

5 October 2011

1 reference

Journal of Cancer Research and Clinical Oncology

25 August 2017

published in

1 reference

25 August 2017

volume

138

1 reference

25 August 2017

issue

2

1 reference

25 August 2017

page(s)

179-187

1 reference

https://scigraph.springernature.com/pub.10.1007/s00432-011-1072-3

25 August 2017

exact match

0 references

cites work

Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1072-3

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1072-3

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1072-3

Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1072-3

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1072-3

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1072-3

Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1072-3

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1072-3

Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1072-3

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1072-3

American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1072-3

Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1072-3

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1072-3

Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study

21 January 2018

1 reference

12 December 2020

Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia

1 reference

12 December 2020

Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia

1 reference

12 December 2020

Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study

1 reference

12 December 2020

Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks

1 reference

12 December 2020

10.1007/S00432-011-1072-3

Identifiers

DOI

1 reference

25 August 2017

1 reference